Haemonetics Corporation disclosed that Director Zane Ellen M acquired 2,538 restricted stock units on July 24, 2026, according to a regulatory filing released July 28, 2026. The RSUs, granted under the company's long-term incentive compensation plan, will vest fully one year from the grant date. The transaction brings Ellen's total direct beneficial ownership of Haemonetics common stock to 21,911 shares.
Key Points
- NYSE: HAE
- Director Zane Ellen M acquired 2,538 restricted stock units on July 24, 2026
- RSUs vest 100% on the first anniversary of the grant date; total direct beneficial ownership increased to 21,911 shares
- Award issued under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan
Details of the Restricted Stock Unit Grant
Zane Ellen M, who serves as a director of Haemonetics Corporation, received an award of 2,538 restricted stock units on July 24, 2026. The disclosure filed with the Securities and Exchange Commission on July 28, 2026, indicates that the RSUs were granted under the company's established long-term incentive compensation framework. Each restricted stock unit represents a contingent right to receive one share of Haemonetics common stock upon vesting, meaning that Ellen's grant carries the potential economic interest equivalent to 2,538 shares of company stock.
The restricted stock units were issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan, a program designed to align the financial interests of company leadership with shareholders. The RSU structure, which requires a one-year vesting period before shares are issued, is a standard approach used by many corporations to encourage long-term executive and director commitment while managing equity dilution over time.
Vesting Schedule and Ownership Timeline
According to the filing, all 2,538 restricted stock units will vest 100 percent on the first anniversary of the grant date. This means that on July 24, 2027, Ellen will receive the full complement of shares represented by the RSU award, assuming she remains in her directorship role. The one-year vesting requirement is typical for director compensation in the healthcare and medical device sectors, where companies seek to maintain director continuity and long-term strategic engagement.
The disclosure reveals that following this transaction, Ellen beneficially owns 21,911 shares of Haemonetics common stock directly. This figure represents her total direct beneficial ownership position in the company, which now includes both her previously held shares and the contingent rights represented by the newly granted RSUs. The company did not disclose the specific price paid for the RSUs or their market valuation at the time of grant in the filing.
Director Compensation and Equity Alignment
Restricted stock unit awards to directors serve multiple corporate governance functions. By tying director compensation to company stock that vests over time, Haemonetics creates a mechanism to ensure that board members maintain a financial stake in the company's long-term performance and strategic decisions. This practice is particularly relevant in the medical technology and blood management sector, where Haemonetics operates, as it helps attract and retain experienced directors who can provide valuable oversight and guidance.
Director equity compensation has become increasingly common in public company governance structures over the past two decades. The approach differs from traditional cash compensation in that it directly links director wealth to shareholder outcomes, theoretically reducing potential conflicts of interest and promoting alignment with investor interests. The one-year vesting schedule also ensures that directors maintain their commitment to the company through a meaningful holding period.
Beneficial Ownership Position Following the Award
The filing documents that Ellen's total direct beneficial ownership of Haemonetics common stock stands at 21,911 shares following the completion of this transaction. This ownership level places Ellen in a position of meaningful equity participation in the company, though the filing does not disclose what percentage of outstanding shares this represents or whether Ellen has any indirect beneficial ownership interests through other entities or arrangements.
The distinction between direct and indirect beneficial ownership is significant in securities law. Direct ownership means that Ellen holds the shares or RSUs in her own name, whereas indirect ownership would include shares held through trusts, family members, or other arrangements where Ellen retains economic interest. The filing indicates that Ellen's 21,911 shares are held directly, representing her personal stake in the company's future performance and shareholder value creation.
Regulatory Filing and Insider Trading Compliance
The disclosure was filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, a federal statute that requires officers, directors, and beneficial owners of more than ten percent of a company's equity securities to report changes in their ownership. This regulatory requirement, commonly known as Form 4 reporting, is intended to provide transparency to the investment community regarding insider transactions and to detect potential insider trading violations.
The filing was signed by Thomas V. Powers, identified as an attorney-in-fact for Ellen, on July 28, 2026, four days after the transaction date of July 24, 2026. SEC regulations typically require Form 4 filings to be submitted within two business days of the transaction date. The filing confirms that the award was not made pursuant to a Rule 10b5-1 trading plan, which is an arrangement that allows insiders to establish predetermined purchase or sale schedules to demonstrate compliance with securities laws.
Long-Term Incentive Compensation Plan Framework
The RSUs were granted under Haemonetics' 2019 Long-Term Incentive Compensation Plan, as amended and restated. This plan is a board-approved equity program that authorizes the company to issue various forms of equity awards, including restricted stock units, stock options, and other incentive securities. Long-term incentive plans serve as the legal and administrative foundation for companies to grant equity compensation to directors, executives, and other eligible participants.
The 2019 plan, which has been amended at least once as evidenced by its "Amended and Restated" designation, represents Haemonetics' primary vehicle for delivering equity-based compensation to its leadership and board members. These plans typically include provisions regarding vesting schedules, exercise prices, plan participation limits, and adjustment mechanisms in the event of corporate transactions or capital adjustments. The fact that Haemonetics maintains such a plan underscores its commitment to equity-based incentive structures as part of its overall compensation strategy.
Insider Trading Notification Requirements
The filing explicitly confirms that Ellen did not complete this transaction pursuant to a contract, instruction, or written plan that would satisfy the affirmative defense conditions of Rule 10b5-1(c). This rule allows corporate insiders to establish pre-arranged trading plans that, if structured properly, can provide safe harbor protection against insider trading liability. The fact that this award was not made under such a plan suggests it was a discretionary grant by the company's board compensation committee rather than part of a predetermined trading arrangement.
Federal securities laws require strict adherence to reporting deadlines and accurate disclosure of all material terms of insider transactions. The filing includes standard SEC language reminding reporting persons that intentional misstatements or omissions of facts in Form 4 filings constitute federal criminal violations under 18 U.S.C. Section 1001 and 15 U.S.C. Section 78ff(a). These provisions carry significant penalties and are intended to ensure the integrity of the insider reporting system that provides transparency to public investors.
Market Context and Investor Implications
The timing of this RSU award to a Haemonetics director in July 2026 adds to the body of public information regarding board-level decisions and compensation decisions at the company. While individual director equity awards may not move company stock prices materially on their own, they form part of the overall pattern of board engagement and compensation that investors monitor. The award reflects the company's ongoing commitment to director compensation through equity participation rather than exclusively through cash payments.
Investors analyzing Haemonetics may use insider transaction disclosures like this one as one data point among many when evaluating board composition, director engagement, and management's confidence in the company's future prospects. The fact that the company is granting equity to its directors suggests confidence in its long-term value creation potential. The immediate share price impact was not clear from available public information. Investors should consider this filing within the broader context of the company's quarterly financial results, market position, and strategic initiatives.



Please wait processing your request...